Image provided by: Texas A&M University
About The Battalion. (College Station, Tex.) 1893-current | View Entire Issue (Sept. 11, 2002)
„ tuf I j V relationships. worship. prayer, the Bible. small groups. simplicity, learning. diversity. authenticity. ...things that are important to us. communityCHURCH WWW.COmCHURCH.com Meeting in Oakwood Intermediate School, 106 Holik, just off George Bush behind the College Station Conference Center Follow the Signs! Sundays: 10:00 a.m. - Prayer Service 10:00 a.m. - KIDS Church 11:00 a.m. - Worship and Bible Study Small Groups meet throughout the week. Call 260-1163 or visit our website for more info. Pastors: Ross King, Scot Stolz, & Worth Whitley Need a New Creative Outlet? lose the air guitar arid learn how to play for real Complete listing of classes at uplus.tamu.edu. Register for Classes Now! Ol I |C£ located in the MSC basement - 845-1631 6A Wednesday, September 11, 2002 NATl HE BATTai N ? WS Till-. BATT; House committee requests Martha Stewart investigatioi Honor Continued WASHINGTON (AP) — Lawmakers asked the Justice Department on Tuesday to begin a criminal investigation into whether Martha Stewart lied to a House committee trying to deter mine if she received inside infor mation before selling her ImClone stock. “As members of Congress we believe it is our obligation to for ward specific and credible infor mation in our possession that could suggest a federal crime has been committed,” the Republican and Democratic leaders of the House Energy and Commerce Committee wrote to Attorney General John Ashcroft. Shares of Stewart’s company, Martha Stewart Omnimedia, jumped almost 10 percent on a surge in volume immediately after the lawmakers' announce ment Tuesday afternoon. The shares closed Tuesday at $9.05. up $1.30, or 16.8 percent, from a day earlier in afternoon trading on the New York Stock Exchange. Stewart’s attorneys said they welcomed the committee’s action because the Justice Department is the appropriate authority to address questions related to her stock sale. “I strongly disagree with the analysis of the committee and its staff but am pleased that the mat ter will now be exclusively in the hands of professional law enforcement authorities who are trained to conduct a responsible and thorough investigation, said Stewart attorney Robert Morvillo. Stew till is a friend of fonner ImClone chief executive Sam Waksal, the only person so tar charged in the federal investiga tion of ImClone Systems Inc., which he founded. He pleaded innocent last month to charges of securities fraud, perjury, bank fraud and obstruction of justice. Stewart sold nearly 4.(XX) shares of ImClone stock on Dec. 27, a day before the company’s application for federal review of its promising colon cancer drug. Erbitux, was denied. Committee spokesman Ken Johnson said panel investigators negotiated with Stewart’s attor neys until shortly before the announcement, ofTering not to seek a Justice Department probe if she would agree to appear vol untarily and testify at a hearing next week. In the letter, the lawmakers said they have been prevented from resolving discrepancies and “suspicious communications” involving the stock sak domestic design tycoon has refused repeatedly to be inter viewed by committee stall mem bers. they said, and her attorneys have said Stewart, if subpoenaed, would invoke her fifth Amendment right not to incnmi- nate herself. Evidence obtained by the committee "cause us to be deeply skeptical of Ms. Stewan s accounts and raise a serious ques tion as to w hether th were false, re ‘ designed to co facts.” the letter t It said the i Stewart’s trading because of questio ble misbehavior insiders and other sons” and because she is a pn»mi- neni public figure who heads a publicly traded company. ‘That is quite different from your average little investor sitting at home in the kitchen. Rep. Jim Greenwood, R-Pa.. chairman of the panel’s investigative subcom mittee. said at a new s conference He noted that Stewan is chief executive officer of her com pans as well as a director of the New York Stock Exchange and a for mer stockbroker. The request for Justice at. ci isieaatng ice a I mat > Ashcroft tvestigatio was warn >ns about p by corpn ‘favored unts sand of ted Tumors linked to cell phones BALTIMORE (AP) — In what could bolster an $800 million lawsuit against Motorola and major cell phone carriers, a new study found a possible link between older cell phones and brain tumors. Although many studies have found no cancer risk from cell phone use, the research published in the latest European Journal of Cancer Prevention said long-term users of analog phones are at least 30 percent more likely than nonusers to 44 develop brain tumors. Newer digital phones emit less radiation than older analog models of the sort studied. The lawsuit against cell phone manufacturer Motorola was brought by Christopher Newman, a Maryland doctor stricken with brain cancer. A federal judge is expected to decide by month's end whether case should go to trial and if so, whether the study can be used as evidence. “From our perspective, and from a public health perspective, the court should just be aware of what’s out there,” said Newman’s lawyer, John Angelos, whose firm has made millions suing asbestos and tobacco companies. If the case is allowed to go forward, it could open the door to other major lawsuits against the communication industry. So far, no similar claims have been successful. Front our perspective y and from a public health perspective, the court should be aware of what’s just out there. -John Angelos Lawyer i Gontraceptive Injection con-troi ^ou-tmrxk a&ou-t jus-t H-*avjear medroxyprogesterone acetate injectable suspension DEPO-PROVERA' Contraceptive Injection (medroxyprogesterone acetate injectable suspension, USP) This product is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted diseases. What is DEPO-PROVERA Contraceptive Injection? DEPO-PROVERA Contraceptive Injection is a form of birth control that is given as an intramuscular injection (a shot) in the buttock or upper arm once every 3 months (I 3 weeks). To continue your contraceptive protection, you must return for your next injection promptly at the end of 3 months f I 3 weeks). DEPO-PROVERA contains medroxyprogesterone acetate, a chemical similar to (but not the same asJ the natural hormone progesterone, which is produced by your ovaries during the second half of your menstrual cycle. DEPO-PROVERA acts by i egg is not released from the ovaries during v (medroxyprogesterone acetate or any of its other using DEPO-PROVERA preventing your egg cells from ripening. If i n _ r menstruaf cycle, it cannot become fertilized by sperm and result in pregnancy. DEPO-PI “kely for prej iring your roVera pregnancy to occur. lining ot your u How effectivels DEPO-PROVERA Contraceptive Injection? The efficacy of DEPO-PROVERA Contraceptive Injection depends on following the recommended dosage schedule exactly (see "How often do I get my shot of DEPO-PROVERA Contraceptive Injection?"). To make sure you are not pregnant when you first get DEPO-PROVERA Contraceptive Injection, your first injection must be given <i>NLY during the first 5 days of a normal menstrual period: ONLY within the first 5 days after childbirth if not breast-feeding; and. if exclusively breast-feeding, ONLY at the sixth week after childbirth. It is a long-term injectable contraceptive when administered at 3-month (13-week) intervals. DEPO-PROVERA Contraceptive Injection is over 99% effective, making it one of the most reliable methods of birth control available. This means that the average annual pregnancy rate is less than one for every 100 women who use DEPO-PROVERA. The effectiveness of rpost contraceptive methods depends in part on how reliably each woman uses the method. The effectiveness of DEPO-PROVERA depends only on the patient returning every 3 months (I 3 weeks) for her next injection. Your health-care provider will help you compare DEPO-PROVERA with other contraceptive methods and give you the information you need in order to decide which Maaafamgmm ^^ choice f • if you have had cancer of the breast • if you have had a stroke • if you have or have had blood clots (phlebitis) in your legs • if you have problems with your liver or liver disease • if you are allergic to DEPO-PROVERA (i ingredients). What other things should I consider before Contraceptive Injection? You will have a physical examination before your doctor prescribes DEPO-PROVERA. It is important to tell your health-care provider if you have any of the following: • a family history of breast cancer • an abnormal mammogram (breast x-ray), fibrocystic breast disease, breast nodules or lumps, or bleeding from your nipples • kidney disease • irregular or scanty menstrual periods • high blood pressure • migraine headaches • asthma • epilepsy (convulsions or seizures) • diabetes or a family history of diabetes • a history of depression • if you are taking any prescription or over-the-counter medications This product is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted diseases such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and syphilis DEPO-PROVERA ' following an injection dicatrng a possible clot i your eyesight or want to become pregnant after using DEPO-PROVERA Contraceptive approximate^ 2.75 pounds peTyeYr. average total of l6 - 5 Pounds over those 6 years, o Because DEPO-PROVERA is a long-acting birth control method, it takes some time after your last In TcTmcaf studvTf over t Qrva fo^'wnmen' \A^v-Tstr>n°i wo-nrep^ »? 7 ^rs. sons contraceptive method is the right : for you. > different kinds of The following table shows the percent of women who got pregnant while contraceptive methods. It gives both the lowest expected rate of pregnancy (tne rate expected in women who use each method exactly as it should be used) and the typical rate of pregnancy (which includes women who became pregnant because they forgot to use their birth control or because they did not follow the directions exactly). Percent of Women Experiencing an Accidental Pregnancy in the First Year of Continuous Use What if Injection? Because DEPO-PROVERA injection for its effect to we; for women who stop using DEPO-PROVERA in order to become pregnant it is' expectedThat about half of those who become pregnant will do so in about 10 months after their last iniection- about two thirds of those who become pregnant will do so in about I 2 months- about 8396 of those who become pregnant will do so in about I 5 months; and about 9396 of those who become KSIP? u° ,n 1 8 rnonths after their last injection. The length of time you use DEPO-PROVERA has no effect on how longit takesyou to become pregnant after you stop usme it What are the risks of using DEPO-PROVERA Contraceptive Injection? ^ Urregular Menstrual Bleeding ' d 6.Other Risks Women who use hormone-based contraceptives may have an increase* stroke. Also, if a contraceptive method fails, there is a possibility that the to develop outside of the uterus (ectopic pregnancy) While these ever tell your health-care provider .f you have any of the probw • Contra cujplftvo^njoction? 8 '° nal Pr0b '- m * " h »* of'oliPO PROVERA provlder immediately if any of these problems oco • sharp chest pain, coughing up of Wood, or sudden shortness of breath (i in tne lung) • sudden severe headache or vomiting, dizziness or fainting problems wii speech, weakness, or numbness in an arm or leg (indicating a oossible ■ • severe pain or swelling ,n the calf (indicating a possible clot in the leal • unusually heavy vaginal bleeding mm* wgj • severe pain or tenderness in the lower abdominal area P u! " °r bleeding at the iniection site i We* ar “ ,*n poss,bl ° s,de eHects °< DEPO-PROVERA Contraceptive Injection? foe s^menTho'C^D^TSoVERA in^r t"! , US '? 8 “PO^OVERA About two third, of during ,hc first year of use. You 8 average total of I pounds H° r ! *£! * wwd who continued for £ years gamed an av£age ^ The side effect reported Method Lowest Expected Typical DEPO-PROVERA 0.3 0.3 Implants (Norplant) 0.2* 0.2* - Female sterilization 0.2 0.4 Male sterilization 0.1 0.15 Oral contraceptive (pill) 3 Combined 0.1 Progestogen only 0.5 IUD 3 Progestasert 2.0 Copper T 3 BOA 0.8 Condom (without spermicide) 2 12 Diaphragm (with spermicide) 6 18 Cervical cap 6 18 Withdrawal 4 18 Periodic abstinence 1-9 20 Spermicide alone 3 21 Vaginal Sponge used before childbirth 6 18 used after childbirth 9 28 No method 85 B5 most frequently by women who use DEPO-PROVERA for ! n t heir normal menstrual cycle. During the first year of using ^ tPC - > :r K OVERA. you might have one or more of the following changes: irregular or unpred'ctable bleeding or spotting, an increase or decrease in menstrual bleeding, or no bleeding at T-V U T us . ua "y heav y or continuous bleeding, however, is not a usual effect of DEPO-PROVERA rxcDr>, t DDA\/i!cfA S 'u?! ,OU _j Should see your hea ' th - care provider right away. With continued use of H ^ ,RA. O'oodmg usually decreases, and many women stop having periods completely fn clinical studies of DEPO-PROVERA, 55% of the women studied reported no menstrual b ceding (amenorrhea) after I year of use, and 68% of the women studied reported no menstrual bleeding after 2 years of use. The reason that your periods stop is because DEPO-PROVERA causes a resting state in your ovaries. When your ovaries do not release an egg monthly, the regular monthly growth of the lining of your uterus does not occur and, therefore, the bleeding rJcda your normal menstruation does not take place. When you stop using ‘^'“^-'■•'I'OvFRA your menstrual period will usually, in time, return to its normal cycle. 2.Bone Mineral Changes Use of DEPO-PROVERA may be associated with a decrease in the amount of mineral stored in your bones. This could increase your risk of developing bone fractures. The rate of bone mineral loss is greatest in the early years of DEPO-PROVERA • - • normal rate of age-related bone mineral loss. J.Cancer who have used different forms of contraception found that women who used r. ' or co . n traception had no increased overall risk of developing cancer of the cramps, d.zz.ness, weakness or fat.gue ' nerv0usr discharge or irritation, breast swelling and terid?me«^lL? ^ cramps. . va S „,ai backache, depression, insomnia, acne pelvic oainn? ha.r sw '° n(i of ,h « hands or flashes, and |0 ,nt pain. Other proWem^w^m mD^ted hfX?"* ha,r lo ”- r « h - h °> trials, but some of these could be serrauT few , of ,he worT ' pn ,n infect'Ons. aHerac reactions, fainting, paralysis os'todS^s^lark^fl a . und,ce - unn ->'> fact thrombosis, pufmonai y embolus breast canrer or k h« um <0 fertility, deep vein Bho ?Ji nn8 your ““ of DEPO-PROVERA dis?uss them l any other^rSbtems Should any precautions be fnllniAsaH Ja vvith your health-care provider. Contraceptive Injection? ollowed during use of DEPO-PROVERA / .Missed Periods During the time you are using DEPO-PROVERA fr»r periods may stop completely If you have been a P« r '°d. or your not pre8nanl Howev ^' f * Wo*^ tesh^nre a aff e £j2cM^ r hormones 4^ soc^f , as i use, but after that, it begins to resemble the effects DEPO-PROVERA. 3.Drug Interactions Cytadr Cytadren (aminoglutethimide) is an antiranr^r a,. „ *u effectiveness of DEPO-PROVERA if the two drug, areUnH may . decrease the 4.Nursing Mothers a are given during the same time Although DEPO-PROVERA can be oassed tn effects nave been found in these ch.ldin DEPO PRoSpir^ 1 ' n producing milk, so it can be K/ o, ^ OV ERA does h. bEPO-pftoVERA that is palsedto Howe ^ r - « 6 weok«; aftf,.- V e ,n ' an t '^i the first weeks the breast milk, no harmful hot prevent the breasts from ulopihg cancer of the How often b r ea^ ov a ry utem s . cervix, or livV. However women under 35 years of age Xs! first Exposure H?e r™i?nT?Sn my V° f , DEPQ-PROVERA Comraceot'ivn i^L„ , y„.^g: P £? V j^- a Vwfth,n the previous 4 ,0 5 years nv£ have,a lightly me,eased^isk of sin^nfoTmu'scufar fen " ' 50 "" — ” Injection? should discuss this with at tKe time of the f.ni i,w» ™ upper arm. T developing breast cancer similar to that seen with oral contraceptives. You sh your health-care provider. 4.Unexpected Pregnancy Because DEPO-PROVERA is such an effective contraceptive method, the risk of accidental followin' «e* • Source: Trussell et al. Obstet Gynecol. 1990:76:558-567. •From Norplant" package insert. Who should not use DEPO-PROVERA Contraceptive Injection? Not all women should use DEPO-PROVERA. You should not use DEPO-PROVERA if you have any of the following conditions: • if you think you might be pregnant • if you have any vaginal bleeding without a known reason XI-uu ve re ports of an increased risk of low birth weight and neonatal infant death should determfne'that' or other health problems in infants conceived close to the time of injection, such pregnancies are uncommon. If you think you may have become pregnant while using DEPO-PROVERA for contraccpt 100 , see your health-care provider as soon as possible. S.AIIergic Reactions Some women using DEPO-PROVERA Contraceptive Injection have reported severe and C XfH tia y '''^-threatening allergic reactions known as anaphylaxis and anaphylactoid reactions, bymptoms include the sudden onset of hives or swelling and itching of tne skin, breathing difficulties, and a drop in blood pressure. & & 5 to--." •*«.- • A. Rx only vrv. d y y P ur health-care provider you your injection of DEPO-PROVERA. Pharmacia & Upjohn Company Kalamazoo. Ml 49001. USA ' Pharmacia & Upjohn CIOUS There acti ’s m committee statements ihat he diii Ikt agents appear !-. ■ .. s \»i by linCk tot speak lo St between Dec. Motorola attorneys criticized the methodolo gy of the new report, which was written by Swedish oncologist Dr. Lennart Hardell. Hardell studied 1,617 patients with brain tumors and compared them with a similar-sized group of people without tumors. He found that patients who used Sweden’s Nordic Mobile telephones were 30 percent more likely to have brain tumors, especially on the side of the head that touched the phone most often. Those who used the phones longer than 10 years were 80 percent more likely to develop tumors. Newman’s lawsuit names Motorola, Verizon and other wireless carriers. He claims the analog cell phones he used from 1992 to 1998 caused him to develop a cancerous brain tumor behind his right ear. The tumor was removed, but Newman is blind in one eye, suffers memory loss and slowed speech and can no longer work, his lawyers say. Cell phones are used by 97 million Americans. Digital phones emit radiation in pulses; older ana log varieties emit continuous waves. By the time cell phones exploded in popularity in the late 1990s, most of those sold used digital technology. Three major studies published since December 2000, including one by the U.S. National Cancer Institute, found no harmful health effects from cell phones. S UK jduri g the <)l last Scptembe 125th annivci s Department action ■Adler was announced b) Greennooc Cantoi l it/gei Rep. Bills Tauzin, R-L. ty-trading inn nutn ot the full committee. I0?i I. 104th: The letter cites ihe Center. He rec Statements Act, whichmaLnuclear chemi felony for anyone to "knok B‘\\ hen sum and willfully make any mi es aw as. there talse statement life, lion by C’lMtgress Ihe pern up to live years in pnsocia r.re Alert Both Justice and tlx? Set. - and Exchange Comir Continued already are investigating insider trading of ImClone sus } j Phone records > 'Namec - ^^■nd phone Willis, spokes! Monies. Iowa. | “W ‘'re here to HUmong 15 H|ie posts embassy in la suin ottiee in ! Iflloiiesia. to V. hat otfieia and speeitie n security threats ] )espite no k aglmsl \meiK annoersaiA an bombs or othe U.S terests a oek sale. u. c j a ] N ne i \ ous et the Food ^ higher threat st ,on was goc 1Ulsh appn level from a of attacks ci —a high danger e, msmssm- ^. imposed since Relief groups tO established in ? give counseling, support on 9/11 analysis and PHILADELPHIA (AP 1,1 U.S. interests i 5. as well that Wuk.s site made Stew ;irt told her rx Lynch bn>l stock if i share. is Stewart '. il did not nr, o him ounr. utee auk' mainuinr: v{X*itdcd VI dispose 3 dropped hell to < befc mat Adr .aw m.ikei ktenrnim re her st on that :t Erbitu to a Attorn Ashcroft said in Red Cross chapters operating a m«*H*UOVornmom. U hut line, setting up " 1 fort stations" with food r°^ L tissues and makr^ g ° emotions unleashe. Wednesday's anniver; H ivCl the terrorist attacks. The Philadelphia ContinU ed fr of the American Red - will run a mental head: r [The attael line Tuesday thro- Americans, ;i rc; Thursday, with counse s j t j r world.” Ai available to help know what othe having difficulty cop' |j n the wak withSept.il- remiondcd with ''With our proximri unity across the New York, we had a lot t f,at lias never e: families affected in economic depn region, and as Sept young Amcricai started to get closet * C o|ne together could see that some pt tragedy. pie were starting to tee ■student Bod some of it," Pat^ remembers the Hastie-Lane, administra'white an d blue of the mental health P patriotism at the gram for the Red Croi S ept. 22. when southeastern Pennsy^'Kyle Field wore chapter ''We anti# bo1d statement c that people are going "It demonstn want to talk about U to stick togeth they're experiencing- Coventry saiti. Americans." Gustav kicks up wind & rain, b^of I American sp no major not st Americans,” Ga HATTERAS, N.C (AP) prikti by the sea Cush Ha Tropical Storm Already one > grazed the Outer Ban'ronsm. the Un.ti on Tuesday, knocking^ power on one of th e ^ er islands and intermittent rain gusts of up to 65 mp • A tropical storm wa was in effect ^ rotri City north to Parr f^j Island, Va., 'n c ^ d Pamlico and Albem sounds and the so Chesapeake Bay. At 5 p.m, Gustav centered about 20 east-northeast of Hatteras, and was nt toward the north at a 10 mph. It was expejj only to brush the Banks and then tu ^ n . which would take i sea, the Naf Hurricane Genter sa lt had sustained W' n shore of 60 mp > gusts to 65 on shore. The National Wea Service said fh ere report of a brief 0 , near Cape Hattera ' a resident James Bergm saw no sign of it.
